Physician profile
Robert G Greenberg
NPI 1639195316
$2,574,820.57
in general payments reported to CMS, 2019-2025
35 companies · $428K in 2025
The $428K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426K · 2020: $198K · 2021: $237K · 2022: $287K · 2023: $466K · 2024: $532K · 2025: $428K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1.0M · Consulting Fee: $187K · Travel and Lodging: $98K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $70K · Food and Beverage: $34K · Honoraria: $260 · Education: $99.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,037,339.01 |
| Consulting Fee | $186,648.48 |
| Travel and Lodging | $98,416.86 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $69,929.23 |
| Food and Beverage | $33,915.82 |
| Honoraria | $260.08 |
| Education | $99.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $339,616.32 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $282,385.13 | 2019-2025 | Ilumya, Blu-U, Absorica Ld |
| Lilly USA, LLC | $269,278.28 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Arcutis Biotherapeutics, INC. | $221,855.59 | 2023-2025 | Zoryve |
| Abbvie INC. | $182,906.94 | 2019-2025 | |
| Ucb, INC. | $172,336.24 | 2019-2025 | Bimzelx, Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $133,718.52 | 2019-2025 | Siliq, Jublia, Cabtreo |
| Janssen Scientific Affairs, LLC | $119,742.20 | 2019-2024 | Tremfya |
| Janssen Biotech, INC. | $117,625.20 | 2019-2025 | Tremfya, Simponi, Stelara |
| Incyte Corporation | $111,695.47 | 2021-2025 | Opzelura, Opzelura |
| Celgene Corporation | $97,483.57 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $84,876.66 | 2019-2025 | Dupixent |
| Pfizer INC. | $83,769.93 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $74,993.86 | 2020-2025 | Sotyktu |
| Genzyme Corporation | $73,947.26 | 2019-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $57,059.01 | 2022-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $48,026.08 | 2019-2025 | |
| Vyne Pharmaceuticals INC. | $40,031.09 | 2020-2021 | |
| Galderma Laboratories, L.P. | $21,375.22 | 2019-2025 | Nemluvio, Aklief |
| Leo Pharma INC. | $16,427.87 | 2020-2025 | Adbry |
| Kowa Pharmaceuticals America, INC. | $7,884.60 | 2025 | Zoryve |
| Mayne Pharma Commercial LLC | $5,116.23 | 2019 | |
| Aclaris Therapeutics, INC. | $4,235.07 | 2019 | |
| Almirall LLC | $3,709.59 | 2019-2025 | Klisyri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,040.07 | 2021-2025 | Spevigo |
| Dermira, INC. | $1,541.16 | 2019 | |
| Promius Pharma LLC | $500.00 | 2019 | |
| Journey Medical Corporation | $323.55 | 2021-2025 | |
| Epi Health, LLC | $148.95 | 2021 | |
| Strata Skin Sciences, INC. | $64.99 | 2022 | |
| Hill Dermaceuticals, INC. | $63.29 | 2025 | Tolak |
| Botanix Sb INC | $25.20 | 2025 | Sofdra |
| Prugen, INC. Pharmaceuticals | $12.85 | 2020 | |
| Organon LLC | $4.58 | 2025 | Vtama |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Greenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.